Infectious mononucleosis is associated with an increased incidence of multiple sclerosis: Results from a cohort study of 32,116 outpatients in Germany.
EBV
MS
epidemiology
incidence
pathophysiology
virus
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
05
2022
accepted:
07
07
2022
entrez:
19
8
2022
pubmed:
20
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
The pathogenesis of multiple sclerosis (MS) has not yet been fully uncovered. There is increasing evidence that Epstein-Barr-Virus (EBV) infection, which affects over 90% of people during life and causes infectious mononucleosis, leads to an increased incidence of MS, and thus may play a crucial role in the pathophysiology of the disease. Using the Disease Analyzer database (IQVIA) featuring diagnoses as well as basic medical and demographic data of outpatients from general practices in Germany, we identified a total of 16,058 patients with infectious mononucleosis that were matched to a cohort of equal size without infectious mononucleosis based on patients' age, sex, index year and yearly consultation frequency. Incidence of MS was compared within a 10-year follow-up period. Within 10 years from the index date, the incidence of MS was 22.6 cases per 100,000 person-years among patient with infectious mononucleosis but only 11.9 cases per 100,000 person-years among individuals without infectious mononucleosis. In regression analysis, infectious mononucleosis was significantly associated with the incidence of MS (HR: 1.86, 95% CI: 1.09-3.16). Subgroup analysis revealed the strongest association between infectious mononucleosis and MS in the age group between 14 and 20 years (HR: 3.52, 95% CI: 1.00-12.37) as well as a stronger association in men compared to women. Infectious mononucleosis is associated with an increased incidence of MS especially in younger individuals. Our data support the growing evidence of a decisive involvement of EBV in the currently unknown pathophysiology of MS and should trigger further research efforts to better understand and potentially prevent cases of this disabling disease in future.
Sections du résumé
Background
The pathogenesis of multiple sclerosis (MS) has not yet been fully uncovered. There is increasing evidence that Epstein-Barr-Virus (EBV) infection, which affects over 90% of people during life and causes infectious mononucleosis, leads to an increased incidence of MS, and thus may play a crucial role in the pathophysiology of the disease.
Methods
Using the Disease Analyzer database (IQVIA) featuring diagnoses as well as basic medical and demographic data of outpatients from general practices in Germany, we identified a total of 16,058 patients with infectious mononucleosis that were matched to a cohort of equal size without infectious mononucleosis based on patients' age, sex, index year and yearly consultation frequency. Incidence of MS was compared within a 10-year follow-up period.
Results
Within 10 years from the index date, the incidence of MS was 22.6 cases per 100,000 person-years among patient with infectious mononucleosis but only 11.9 cases per 100,000 person-years among individuals without infectious mononucleosis. In regression analysis, infectious mononucleosis was significantly associated with the incidence of MS (HR: 1.86, 95% CI: 1.09-3.16). Subgroup analysis revealed the strongest association between infectious mononucleosis and MS in the age group between 14 and 20 years (HR: 3.52, 95% CI: 1.00-12.37) as well as a stronger association in men compared to women.
Conclusion
Infectious mononucleosis is associated with an increased incidence of MS especially in younger individuals. Our data support the growing evidence of a decisive involvement of EBV in the currently unknown pathophysiology of MS and should trigger further research efforts to better understand and potentially prevent cases of this disabling disease in future.
Identifiants
pubmed: 35983044
doi: 10.3389/fimmu.2022.937583
pmc: PMC9379368
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
937583Informations de copyright
Copyright © 2022 Loosen, Doege, Meuth, Luedde, Kostev and Roderburg.
Déclaration de conflit d'intérêts
Author KK was employed by IQVIA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mult Scler. 2011 Oct;17(10):1185-93
pubmed: 21685232
Trends Immunol. 2003 Nov;24(11):584-8
pubmed: 14596882
Front Immunol. 2021 Jun 08;12:677027
pubmed: 34168649
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466
pubmed: 30168417
Neurol Neuroimmunol Neuroinflamm. 2018 Jun 07;5(4):e466
pubmed: 29892607
PLoS One. 2019 Dec 17;14(12):e0226436
pubmed: 31846480
Nature. 2022 Mar;603(7900):321-327
pubmed: 35073561
Neuroepidemiology. 2021;55(2):92-99
pubmed: 33662954
Mult Scler J Exp Transl Clin. 2021 Jun 28;7(2):20552173211022784
pubmed: 34262785
JAMA. 2005 May 25;293(20):2496-500
pubmed: 15914750
J Infect Dis. 2013 Oct 15;208(8):1286-93
pubmed: 23868878
Science. 2022 Jan 21;375(6578):296-301
pubmed: 35025605
Exp Mol Med. 2015 Jan 23;47:e132
pubmed: 25613729
J Exp Med. 2007 Nov 26;204(12):2899-912
pubmed: 17984305
Ann Neurol. 2010 Jun;67(6):824-30
pubmed: 20517945
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Int J Clin Pract. 2021 Oct;75(10):e14690
pubmed: 34331837
Lancet. 2017 Apr 1;389(10076):1336-1346
pubmed: 27889190
Expert Rev Clin Immunol. 2020 Dec;16(12):1143-1157
pubmed: 33152255
Lancet Neurol. 2010 Jul;9(7):727-39
pubmed: 20610348
Brain. 2011 Sep;134(Pt 9):2772-86
pubmed: 21846731
J Neurol Neurosurg Psychiatry. 2020 Jul;91(7):681-686
pubmed: 32371533
Sci Rep. 2022 Jan 19;12(1):1001
pubmed: 35046460
Immunol Res. 2018 Dec;66(6):686-695
pubmed: 30552620
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Front Neuroendocrinol. 2014 Aug;35(3):347-69
pubmed: 24793874
Lancet Neurol. 2019 Mar;18(3):269-285
pubmed: 30679040
Ann Neurol. 2006 Mar;59(3):499-503
pubmed: 16502434